Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 3
2003 4
2004 1
2005 3
2006 6
2007 7
2008 2
2009 5
2010 5
2011 3
2012 6
2013 5
2014 7
2015 4
2016 4
2017 1
2018 1
2019 1
2021 1
2022 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Rilpivirine.
Sanford M. Sanford M. Drugs. 2012 Mar 5;72(4):525-41. doi: 10.2165/11208590-000000000-00000. Drugs. 2012. PMID: 22356290 Review.
Rilpivirine 25 mg once daily recipients had a treatment response (confirmed plasma HIV-1 RNA level of <50 copies/mL at 48 weeks; primary endpoint) that was noninferior to that of efavirenz 600 mg once daily recipients. The response rates in the rilpivirine …
Rilpivirine 25 mg once daily recipients had a treatment response (confirmed plasma HIV-1 RNA level of <50 copies/mL at 48 weeks; p …
Efavirenz.
Maggiolo F. Maggiolo F. Expert Opin Pharmacother. 2007 Jun;8(8):1137-45. doi: 10.1517/14656566.8.8.1137. Expert Opin Pharmacother. 2007. PMID: 17516877 Review.
Efavirenz-based regimens have performed favorably compared with protease inhibitor-based therapies either in naive patients or as simplification strategies in pretreated subjects. Efavirenz is administered once-daily and its simple dosing schedule improves adherence …
Efavirenz-based regimens have performed favorably compared with protease inhibitor-based therapies either in naive patients or as sim …
Pharmacogenomics of antiretrovirals.
Roca B. Roca B. Recent Pat Antiinfect Drug Discov. 2008 Jun;3(2):132-5. doi: 10.2174/157489108784746650. Recent Pat Antiinfect Drug Discov. 2008. PMID: 18673126 Review.
Antiretroviral therapy is especially suitable for pharmacogenomic investigation as both drug exposure and treatment response can be reliably measured. Increasing knowledge about genes implicated in pharmacokinetics, mode of action, efficacy, and toxicity of drugs has alrea …
Antiretroviral therapy is especially suitable for pharmacogenomic investigation as both drug exposure and treatment response can be r …
Pharmacogenetics of antiretrovirals.
Tozzi V. Tozzi V. Antiviral Res. 2010 Jan;85(1):190-200. doi: 10.1016/j.antiviral.2009.09.001. Epub 2009 Sep 8. Antiviral Res. 2010. PMID: 19744523 Review.
Antiretroviral treatment is characterized by differing rates of adverse events and responses. Genetic variations between human beings account for a relevant proportion of this variability. ...Other well-established associations include CYP2B6 alleles and efavirenz c …
Antiretroviral treatment is characterized by differing rates of adverse events and responses. Genetic variations between human beings …
Warfarin-antiretroviral interactions.
Liedtke MD, Rathbun RC. Liedtke MD, et al. Ann Pharmacother. 2009 Feb;43(2):322-8. doi: 10.1345/aph.1L497. Epub 2009 Feb 5. Ann Pharmacother. 2009. PMID: 19196837 Review.
DATA SYNTHESIS: The drugs used in the case reports were limited to 6 antiretroviral agents (efavirenz, nevirapine, lopinavir/ritonavir, nelfinavir, saquinavir, ritonavir). ...When warfarin is used concurrently with antiretrovirals, close monitoring of INR response i …
DATA SYNTHESIS: The drugs used in the case reports were limited to 6 antiretroviral agents (efavirenz, nevirapine, lopinavir/ritonavi …
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Jiang HY, Zhang MN, Chen HJ, Yang Y, Deng M, Ruan B. Jiang HY, et al. Int J Infect Dis. 2014 Aug;25:130-5. doi: 10.1016/j.ijid.2014.04.020. Epub 2014 Jun 6. Int J Infect Dis. 2014. PMID: 24911886 Free article. Review.
METHODS: A comprehensive search of the literature was carried out to identify clinical trials comparing the efficacy and safety of nevirapine- and efavirenz-based ART regimens in HIV-associated TB. Eligible clinical studies included at least one primary or secondary event; …
METHODS: A comprehensive search of the literature was carried out to identify clinical trials comparing the efficacy and safety of nevirapin …
Clinical utility of maraviroc.
Parra J, Portilla J, Pulido F, Sánchez-de la Rosa R, Alonso-Villaverde C, Berenguer J, Blanco JL, Domingo P, Dronda F, Galera C, Gutiérrez F, Kindelán JM, Knobel H, Leal M, López-Aldeguer J, Mariño A, Miralles C, Moltó J, Ortega E, Oteo JA. Parra J, et al. Clin Drug Investig. 2011;31(8):527-542. doi: 10.2165/11590700-000000000-00000. Clin Drug Investig. 2011. PMID: 21595497 Review.

Data from the phase III programme of maraviroc, which includes the MOTIVATE 1 and 2 studies and the MERIT study, indicate that maraviroc significantly (p < 0.001) increases CD4+ cell counts compared with placebo in pre-treated patients and to a similar extent as efavirenz

…
Data from the phase III programme of maraviroc, which includes the MOTIVATE 1 and 2 studies and the MERIT study, indicate that maraviroc sig …
Vascular endothelial dysfunction in the wake of HIV and ART.
Marincowitz C, Genis A, Goswami N, De Boever P, Nawrot TS, Strijdom H. Marincowitz C, et al. FEBS J. 2019 Apr;286(7):1256-1270. doi: 10.1111/febs.14657. Epub 2018 Sep 28. FEBS J. 2019. PMID: 30220106 Free article. Review.
Endothelial dysfunction (loss of endothelium-dependent vascular relaxation in response to provasodilatory stimuli) constitutes an early pathophysiological event in atherogenesis and CVD. ...The HIV-1-proteins Tat, Gp120 and Nef in particular, the proinflammatory cytokine, …
Endothelial dysfunction (loss of endothelium-dependent vascular relaxation in response to provasodilatory stimuli) constitutes an ear …
Efficacy and Tolerability of Integrase Inhibitors in Antiretroviral-Naive Patients.
D'Abbraccio M, Busto A, De Marco M, Figoni M, Maddaloni A, Abrescia N. D'Abbraccio M, et al. AIDS Rev. 2015 Jul-Sep;17(3):171-85. AIDS Rev. 2015. PMID: 26450805 Review.
Drugs in this class have been compared to others in antiretroviral-naive patients with efavirenz and with protease inhibitors. Final results of the STARTMRK trial highlighted the better virologic and immunologic performance of raltegravir over efavirenz/emtricitabin …
Drugs in this class have been compared to others in antiretroviral-naive patients with efavirenz and with protease inhibitors. Final …
Review of drug interactions with telaprevir and antiretrovirals.
van Heeswijk RP, Beumont M, Kauffman RS, Garg V. van Heeswijk RP, et al. Antivir Ther. 2013;18(4):553-60. doi: 10.3851/IMP2527. Epub 2013 Jan 23. Antivir Ther. 2013. PMID: 23344266 Review.
Telaprevir-based treatment has been shown to increase rates of sustained viral response in HCV genotype-1-monoinfected patients, and studies in HCV-HIV-coinfected patients are ongoing. ...This review summarizes the results of interaction studies with low-dose ritonavir, ri …
Telaprevir-based treatment has been shown to increase rates of sustained viral response in HCV genotype-1-monoinfected patients, and …
66 results